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Abstract
Background: Tumor necrosis factor receptor-associated factors (TRAFs) are important signaling molecules for a variety of
pro-atherogenic cytokines including CD40L, TNF a, and IL1b. Several lines of evidence identified TRAF6 as a pro-
inflammatory signaling molecule in vitro and we previously demonstrated overexpression of TRAF6 in human and Murine
atherosclerotic plaques. This study investigated the role of TRAF6-deficiency in mice developing atherosclerosis, a chronic
inflammatory disease.
Methodology/Principal Findings: Lethally irradiated low density lipoprotein receptor-deficient mice (TRAF6
+/+/LDLR
2/2)
were reconstituted with TRAF6-deficient fetal liver cells (FLC) and consumed high cholesterol diet for 18 weeks to assess the
relevance of TRAF6 in hematopoietic cells for atherogenesis. Additionally, TRAF6
+/2/LDLR
2/2 mice received TRAF6-deficient
FLC to gain insight into the role of TRAF6 deficiency in resident cells. Surprisingly, atherosclerotic lesion size did not differ
between the three groups in both aortic roots and abdominal aortas. Similarly, no significant differences in plaque
composition could be observed as assessed by immunohistochemistry for macrophages, lipids, smooth muscle cells, T-cells,
and collagen. In accord, in a small clinical study TRAF6/GAPDH total blood RNA ratios did not differ between groups of
patients with stable coronary heart disease (0.03460.0021, N=178), acute coronary heart disease (0.02960.0027, N=70),
and those without coronary heart disease (0.03260.0016, N=77) as assessed by angiography.
Conclusion: Our study demonstrates that TRAF6 is not required for atherogenesis in mice and does not associate with
clinical disease in humans. These data suggest that pro- and anti-inflammatory features of TRAF6 signaling outweigh each
other in the context of atherosclerosis.
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Introduction
Atherosclerosis, one of the leading causes of morbidity and
mortality in Western countries [1], is a chronic inflammatory
disease driven by an armada of inflammatory cells and their
effector cytokines. A solid body of evidence supports the concept
that inflammation promotes atherogenesis at every step from
initiation to progression, destabilization, and complication.
Although the inflammatory nature of this disease had been
uncovered more than a decade ago a genuine anti-inflammatory
or immune-modulatory treatment option is still absent in current
therapeutic regimens [2]. Along with extensive basic experimental
data increasing clinical evidence attribute great potential to such
therapeutic strategies. The recent JUPITER trial is an example par
excellence in that respect [3]. While unselective inhibition of pro-
inflammatory cytokines such as CD40L initially held great promise
these strategies either proved to have inherent deleterious side
effects or appear unfit for long-term treatment likely required by
the chronic inflammatory nature of atherosclerotic disease [4].
Selective inhibition of key signaling branch points, however, may
overcome some of these limitations and demonstrated feasibility in
the treatment of other disorders such as malignancies.
Tumor necrosis factor (TNF) receptor-associated factors
(TRAFs) are intracellular adaptor proteins, which channel
signaling for members of the TNF-/interleukin-1 (IL-1)-/toll-
like-receptor (TLR)-superfamily such as TNFa, CD40L, and IL-
1b, proteins known to promote inflammation and atherosclerosis
[5,6,7]. To date seven TRAFs have been characterized sharing a
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receptors and with the exception of TRAF1 sharing a RING-zinc
finger for downstream signal propagation [8,9]. TRAF6, a 63 kDa
molecule, was first identified as an adaptor protein of CD40 and
independently as a signal transducer for IL-1 [10,11]. TRAF6
differs from the other TRAFs in recognizing a distinguished amino
acid sequence allowing for participation in inflammatory signaling
of both the TNFR and IL1/Toll-like receptor pathways
[12,13,14]. While overexpression of TRAF6 induces NFkB
activation, dominant negative mutants of TRAF6 inhibit the
NFkB pathway activated by IL-1b but not TNFa[10,15,16].
Interestingly, cells with mutant CD40 molecules eliminating the
interaction with TRAF6 showed impaired NFkB, JNK, and p38
activation [17]. Similarly, IL-1b-mediated activation of these
molecules was completely abrogated in TRAF6-deficient mixed
embryonic fibroblasts [18]. Furthermore, expression of exogenous
TRAF6 in TRAF6-deficient cells restored NFkB, JNK, and p38
phosphorylation [19]. These data suggest that TRAF6 figures as
pro-inflammatory molecule.
Data on the function of TRAF6 in vascular disease are scarce.
Human monocytes transfected with TRAF6 binding protein
inhibiting the association of TRAF6 with CD40, failed to
activate ERK1/2, IKK, and cytokine production after stimu-
lation with CD40L [20]. Donners et al. demonstrated that mice
carrying a mutated TRAF6 with selective incapability of CD40
binding develop decreased neointima formation in a carotid
injury model. Similar findings were also obtained in rabbits
upon transfection of a plasmid containing the dominant
negative form of TRAF6 [21,22]. Our group recently demon-
strated overexpression of several TRAFs including TRAF6 in
Murine and human atherosclerotic lesions [23]. Based on these
data we hypothesized that TRAF6 promotes atherogenesis in
mice and associates with atherosclerosis and its complications in
humans.
Results
Fetal liver cell transplantation successfully reconstitutes
hematopoeietic cells
Exploration of atherogenesis in TRAF6-deficient mice was
hampered by the limited viability of homozygous TRAF6-deficient
mice [15,16]. To circumvent this limitation we performed fetal
liver cell (FLC) transplantations. To test the hypothesis that
TRAF6 in FLC-derived cells contributes to atherogenesis, FLC
from TRAF6
2/2/LDLR
2/2 and TRAF6
+/+/LDLR
2/2 were
transplanted into TRAF6
+/+/LDLR
2/2 mice. To explore a
putative additional effect of TRAF6 in resident cells such as
endothelial cells and smooth muscle cells, a third group of chimera
was generated by transplanting FLC from TRAF6
2/2/LDLR
2/2
into TRAF6
+/2/LDLR
2/2 mice. In this model, transplantation
of FLC from CD45.2 mice into CD45.1 recipients validated
successful reconstitution of CD3-, CD19-, and CD11b-positive
cells in our hands (Fig. 1). Furthermore, spleens of both TRAF6
+/+/
LDLR
2/2 and TRAF6
+/2/LDLR
2/2 mice receiving TRAF6-
deficient FLC showed impaired TRAF6/GAPDH mRNA expres-
sion as assessed by quantitative PCR, also indicating successful
reconstitution (Fig. 2A).
To verify the assumption that TRAF6 heterozygous mice
express lower levels of TRAF6, we also analyzed TRAF6
expression in spleens and aortas of TRAF6
+/+/LDLR
2/2 and
TRAF6
+/2/LDLR
2/2 animals without transplantation. In both
cases, TRAF6 heterozygous mice expressed lower TRAF6/
GAPDH mRNA ratios (Fig. 2B and C).
TRAF6 deficiency attenuates weight gain and plasma
cholesterol increase on high cholesterol diet
After 4 weeks allowed for reconstitution, mice consumed a high
cholesterol diet for 18 weeks. At the beginning of the study no
significant difference in body weight, plasma cholesterol, triglycer-
ide levels, and phenotype was observed (Fig. 3A–C). However, all
groups receiving TRAF6-deficient FLC had significantly lower
peripheral leukocyte counts, an effect that could no longer be
detected after the feeding period (Fig. 3D). No difference could be
detected as to the percentage of the T cell subtypes CD4, CD8, and
Tregs, of the inflammatory monocyte subset Ly6C
high monocytes,
and the percentage of B cells (Table 1). At the end of the study
TRAF6
+/+/LDLR
2/2 mice reconstituted with TRAF6-deficient
cells (24.061.1 g, N=22) weighed significantly less than TRAF6
+/+/
LDLR
2/2 mice receiving TRAF6-competent FLC (31.5 g61.1 g,
N=27. p,0.0001). TRAF6
+/2/LDLR
2/2 mice reconstituted with
TRAF6-deficient cells did not gain weight at all on HCD
(20.5 g60.7 g, N=24, p,0.0001, Fig. 3A).
Also, TRAF6
+/+/LDLR
2/2 mice receiving TRAF6-deficient
FLC (496646 mg/dl, N=21) had significantly lower plasma
cholesterol levels than those receiving TRAF6-competent FLC
(730 mg/dl636 mg/dl, N=23, p=0.002) after 18 weeks of HCD
while no significant difference in cholesterol levels could be
detected when compared with TRAF6
+/2/LDLR
2/2 mice
receiving TRAF6-deficient FLC (620 mg/dl641 mg/dl, N=22,
p=0,0513 Fig. 3B). There were no significant differences in
triglycerides between the tested groups.
TRAF6 deficiency does not alter atherosclerotic lesion
size and plaque composition in aortic roots
Intimal lesion size in the aortic roots of TRAF6
+/+/LDLR
2/2
(0.199 mm
260.04 mm
2, N=21, p=0.2825) and TRAF6
+/2/
LDLR
2/2 mice (0.198 mm
260.03 mm
2 N=22, p=0.7178)
reconstituted with TRAF6-deficient FLC did not differ compared
with TRAF6
+/+/LDLR
2/2 mice receiving TRAF6-competent
FLC (0.213 mm
260.03 mm
2, N=21, Fig. 4). Next we tested
whether TRAF6, though not altering lesion size, modulates
cellular composition of the atherosclerotic plaque. TRAF6
deficiency did not change lesional macrophage-, lipid-, collagen-,
smooth muscle cell-, or T-cell- content, suggesting no relevant
effect of TRAF6 on atherosclerotic plaque formation (Fig. 5).
TRAF6 deficiency does not modulate atherosclerosis in
the abdominal aorta
Since effects on atherogenesis may be site- and stage-specific we
also analyzed lesion formation en face in the abdominal aortas [24].
As expected, lesion formation was reduced in abdominal aortas, a
phenomenon known in animals that underwent irradiation [25].
Again, TRAF6 deficiency did not alter lesion size as assessed by
Oil red O staining (Fig. 6).
TRAF6 deficiency does modulate the inflammatory gene
expression of macrophages
Since TRAF6
+/+/LDLR
2/2 and TRAF6
+2/LDLR
2/2 mice
showed decreased levels of cholesterol at the end of the study
(Fig. 3B) a putative difference in macrophage reactivity toward
cholesterol or fatty acids could explain why we observed similar
atherosclerotic lesion formation in these mice compared with
respective wild-type controls and could therefore mask a
phenotype. Thus, we isolated bone marrow-derived macrophages
from TRAF6
+/+/LDLR
2/2 mice reconstituted with either
TRAF6-deficient or -competent FLC and stimulated these with
cholesterol and palmitic acid. Interestingly, macrophages from
TRAF6 and Atherosclerosis
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monocyte chemoattractant protein-1 (MCP-1), tumor necrosis
factor alpha (TNFa), and interleukin-12 (IL-12) as assessed by
cytometric bead array (Fig. 7), suggesting that our observations are
not due to a TRAF6-dependent difference in inflammatory
reactivity of macrophages.
TRAF6 mRNA expression in blood does not associate
with acute or chronic coronary heart disease in humans
Since we previously demonstrated overexpression of TRAF6
protein in human plaques, we tested the hypothesis that TRAF6
expression associates with acute or chronic coronary heart disease
in humans [23]. Therefore, we measured TRAF6 mRNA in blood
of a total of 325 patients undergoing coronary angiography
categorized into three groups: no coronary heart disease (No CHD,
N=77), stable coronary heart disease (CHD, N=178), and acute
coronary syndrome (ACS, N=70). The baseline characteristics of
the study groups have been previously published [26] and are
shown in table 2. Gender and BMI did not significantly differ
among the groups, while patients were older in the CHD group and
had more traditional cardiovascular risk factors in the CHD and
ACS groups. TRAF6/GAPDH mRNA ratios did not differ
betweenthegroupscorroboratingthedatagatheredinmice(Fig.8).
Discussion
The current study presents the novel and unexpected finding
that TRAF6 deficiency on FLC-derived cells does not alter
atherogenesis in either TRAF6
+/+/LDLR
2/2 or TRAF6
+/2/
LDLR
2/2 mice. Our data challenge the common view of TRAF6
as pro-inflammatory signaling molecule in the context of
atherosclerosis.
Multiple reports identified TRAF6 as positive regulator of
CD40L- and IL-1 but not TNFa-induced NFkB signaling
[10,15,16,17,27] in vitro. Furthermore, TRAF6 is essential for
signaling via the toll-like receptors 2, 5, 7, and 9 but not -3 [27]. In
vivo evaluation of the genetic deficiency in TRAF6 confirmed its
role in CD40-, IL-1-, and LPS signaling and phenotypically
resulted in severe osteopetrosis [15,16]. In line with a pro-
inflammatory function of TRAF6 Kobayashi et al. reported
impaired maturation of TRAF6-deficient dendritic cells in vitro
and in vivo [18], a cell type crucially involved in adaptive immunity
by presenting antigens to T cells [28]. Similarly, two previous
reports implicated TRAF6 with neointima formation [21,22]. In
contrast, our data suggest no role for TRAF6 in the chronic
inflammatory disease atherosclerosis. Although TRAF6 deficiency
impaired weight gain and decreased plasma cholesterol levels,
attributes that would commonly favor smaller atherosclerotic
lesions, TRAF6 deficiency did not reduce plaque formation. These
data are in accord with our previous report demonstrating no
modulation of atherogenesis for the TRAF6 cognate receptor
CD40 [29]. Interestingly, Akiyama et al. reported a disrupted
thymic structure, reduced numbers of regulatory T cells, and an
autoimmune phenotype with inflammatory infiltrates in most
organs in TRAF6-deficient mice, suggesting rather an anti-
inflammatory role for TRAF6 [30]. These opposing results
demonstrate that TRAF functions may be diverse and depend
indeed on stimulus and cell type warranting a disease-based
evaluation [8]. Of note, TRAF6-competent and -deficient
macrophages responded similarly to stimulation with cholesterol
and acid palmitic acid suggesting that our findings are not due to a
TRAF6-dependent difference in inflammatory reactivity.
Recently, Lutgens et al. found reduced atherosclerotic lesion
formation in mice lacking the binding site for TRAF6 on CD40 in
monocytes/macrophages [31]. Our data are not in contrast with
this finding. Specific CD40-TRAF6 signaling may very well be
pro-atherogenic while overall signaling through TRAF6 by various
upstream receptors may have no net effect on atherogenesis.
Figure 2. Mice reconstituted with TRAF6-deficient fetal liver cells and TRAF6 heterozygous mice express less TRAF6 than controls.
Lethally irradiated 6 week old TRAF6
+/+/LDLR
2/2 mice received TRAF6-deficient (N=4) or competent fetal liver cells (N=4), TRAF6
+/2/LDLR
2/2 mice
received TRAF6-deficient fetal liver cells (N=2) only. RNA was isolated from spleens. Ratios of TRAF6/GAPDH mRNA as assessed by quantitative RT-
PCR are shown as mean6SEM (A). RNA was isolated from spleens (B) and aortas (C) of TRAF6
+/+/LDLR
2/2 (N=5 and 3) TRAF6
+/2/LDLR
2/2 mice (N=3
and 2). Ratios of TRAF6/GAPDH mRNA as assessed by quantitative RT-PCR are shown as mean6SEM.
doi:10.1371/journal.pone.0011589.g002
Figure 1. Successful reconstitution of peripheral blood cells by fetal liver cell transplantation. LDLR
2/2 mice (CD45.2-positive/CD45.1-
negative, A) were lethally irradiated (26450 cGy) and reconstituted with fetal liver cells of 6–8 week old CD45.1-positive/CD45.2-negative mice (B).
After an interval of 4 weeks, peripheral blood cells were immunostained with CD45.1-PE and CD45.2-FITC (exemplary donors are shown in C and D) or
CD45.1-PE in combination with CD19-PECy (B-cell marker, E), CD3-APC (T-cell marker, F), and CD11b-FITC (monocytic marker, G) antibodies and
analyzed by FACS.
doi:10.1371/journal.pone.0011589.g001
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IL1b, and TLR4 are well known propagators of atherogenesis
[6,7,32]. However, TRAF6 also interacts with proteins known to
attenuate atherosclerotic lesion formation: recently it could be
shown, that TLR5- deficient mice develop a metabolic syndrome
[33]. Moreover, Miller et al. reported an anti-atherogenic effect of
IL-33 [34], which also signals through TRAF6 [35]. Thus,
TRAF6 may initiate anti-inflammatory signals outweighing its
pro-inflammatory attributes. In line with this notion, we previously
demonstrated increased expression of IL-6, MCP-1, and IL-8 in
the supernatants of TRAF6-silenced human umbilical vein
endothelial cells (HUVEC) upon stimulation with CD40L and
TNFa in endothelial cells and bone marrow-derived macrophages
[23].
Several studies implicate TRAF6 in the recruitment and
function of mononuclear cells [21,31]. Mukundan et al. reported
that TRAF6 is crucial in CD40-mediated activation of ERK1/2
NFkB, and inflammatory cytokine production [20]. However,
these findings were not reflected by a change in lesional
macrophage content in our study. Not only did plaque size not
differ between the study groups but also lesion composition was
similar in the present study, again suggesting that the pro-
inflammatory features of TRAF6 are counterbalanced in athero-
genesis.
Figure 3. Weights, cholesterol-, and leukocyte levels before and after high cholesterol diet. Lethally irradiated 6 week old TRAF6
+/+/
LDLR
2/2 mice received TRAF6-deficient (hatched bars, N=22) or competent fetal liver cells (white bars, N=27), TRAF6
+/2/LDLR
2/2 mice received
TRAF6-deficient fetal liver cells (black bar, N=23) only. Subsequently, all groups consumed high cholesterol diet (HCD) for 18 weeks. Weights (A),
plasma cholesterol levels (B), triglycerides (C), and leukocyte counts (D) were taken before and after HCD.
doi:10.1371/journal.pone.0011589.g003
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in human carotid plaques we tested whether TRAF6 mRNA
levels in blood associate with chronic or acute coronary heart
disease. We observed no significant difference in TRAF6
expression between the tested groups: no coronary heart disease
(no CHD), stable coronary heart disease (CHD) and acute
coronary syndrome (ACS), corroborating our findings obtained in
mice.
Our studyhasseveral limitations:First, we cannot ruleout that the
lower cholesterol levels observed in animals receiving TRAF6-
deficient bone marrow mask a putative effect of TRAF6 deficiency.
Thisis,however,unlikelysincepreviousreportsmainlysuggestapro-
inflammatory function of TRAF6 and therefore one would expect
reduced levels of atherosclerosis in mice deficient in TRAF6. Lower
cholesterol levels also predispose for smaller lesions. Therefore, these
should not impair the results of our study. Furthermore, we found no
Figure 4. TRAF6 deficiency does not modulate atherogenesis in mice. Lethally irradiated 6 week old TRAF6
+/+/LDLR
2/2 mice received
TRAF6-deficient (hatched bars, N=21) or competent fetal liver cells (white bars, N=21), TRAF6
+/2/LDLR
2/2 mice received TRAF6-deficient fetal liver
cells (black bars, N=22) only. Subsequently, all groups consumed high cholesterol diet (HCD) for 18 weeks. Intimal lesion area of the atherosclerotic
plaques in aortic roots was quantified. Pooled mean intimal lesion area 6 SEM are shown as graphs in the upper panel (A), representative sections
stained with oil red O below (B).
doi:10.1371/journal.pone.0011589.g004
Table 1. Subtypes of blood leukocytes.
TRAF6
+/+/LDLR
2/2 TRAF6
+/2/LDLR
2/2
TRAF6
+/+/LDLR
2/2 in
TRAF6
+/+/LDLR
2/2
TRAF6
2/2/LDLR
2/2 in
TRAF6
+/+/LDLR
2/2
TRAF6
2/2/LDLR
2/2 in
TRAF6
+/2/LDLR
2/2
CD4+% of T- cells 51.266.7 55.963.5 65.961.1 63.662.5 65.061.3
CD8+% of T- cells 37.062.6 38.163.5 28.261.0 28.365.0 28.563.4
T- reg% of T- cells 3.762.3 3.462.3 3.462.4 4.562.0 6.6
B- cells% of leukocytes 23.9613.0 23.864.7 20.662.2 19.564.1 20.9
Inflammatory monocytes %
of total monocytes
65.6619.7 67.4613.8 65.0612.2 63.4623.4 70.6
doi:10.1371/journal.pone.0011589.t001
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of macrophages, which could also mask a putative effect of TRAF6 in
our model. Secondly, since c-irradiation itself profoundly influences
the development of atherosclerotic lesions we cannot rule out that this
affects our results [25]. However, all groups were treated equally.
Therefore, differences should still be detected between the groups.
In summary, we present the novel and surprising finding that
TRAF6 deficiency does not influence atherogenesis in mice and
does not associate with atherosclerosis in humans. Therefore,
overall targeting of TRAF6 may not be a promising treatment
strategy for atherosclerosis and probably also other chronic
inflammatory diseases.
Figure 5. TRAF6 deficiency does not alter plaque composition. Lethally irradiated 6 week old TRAF6
+/+/LDLR
2/2 mice received TRAF6-
deficient (hatched bars, N=21) or competent fetal liver cells (white bars, N=21), TRAF6
+/2/LDLR
2/2 mice received TRAF6-deficient fetal liver cells
(black bars, N=22) only. Subsequently, all groups consumed high cholesterol diet (HCD) for 18 weeks. Sections of the aortic roots were analyzed for
macrophage- (A), lipid- (B), smooth muscle cell- (C), collagen (D), and T cell-content (E). Mac-3-, oil-red-O-, a-actin-, picrosirius red, and CD4-positive
staining in per cent of total wall area is displayed as mean6SEM.
doi:10.1371/journal.pone.0011589.g005
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Genotyping and housing of Mice
All animal procedures were approved by the Animal Board of
Freiburg (Regierungspra ¨sidium Freiburg, permit number G05/
41). TRAF6
+/2 mice were kindly provided by Dr. T. W. Mak and
fully backcrossed to C57/BL6 background as verified by
background strain characterization at Jackson laboratories. Mice
were crossbred with LDLR
2/2 mice (Jackson) to generate
TRAF6
+/2/LDLR
2/2 and TRAF6
+/+/LDLR
2/2 mice. Geno-
typing of each mouse used polymerase chain reaction employing
the following primers: LDLR, 59-CCA TAT GCA TCC CCA
GTC TT-39 (common primer), 59-GCG ATG GAT ACA CTC
ACT GC-39 (wild-type primer), 59-AAT CCA TCT TGT TCA
ATG GCC GAT C-39 (mutant primer); TRAF6, 59-CTG CAG
TGA AAG ATG ACA GCG TGA GT-39 (wild-type) ; 59-CCA
AGT GCC CAG CGG GGC TGC TAA AG -39 (neo), 59-ACG
GAA GCA AGC CTC TGT TCA TAC CG-39 (common). All
mice were housed under specific pathogen-free conditions.
Fetal Liver Cell Transplantation
Fetal livers were obtained 17 days after conception from fetuses
of TRAF6
+/2/LDLR
2/2 mice. One arm was used for genotyp-
ing. Four week-old male TRAF6
+/+/LDLR
2/2 and TRAF6
+/2/
LDLR
2/2 recipient mice were lethally irradiated with two doses
of 450 cGy at a 6 h interval (Gammacell Exactor 40). Fetal livers
were suspended with a pipette, filtered through a 100 mm cell
strainer (BD bioscience), centrifuged, resuspended, and injected at
10
6 cells/300 ml into the tail vein. Transplanted mice received
chow diet for four weeks allowing for reconstitution. To verify
reconstitution, fetal liver cells from CD45.1 mice were transplant-
ed into CD45.2 mice and reconstitution rates were assessed by
FACS after 4 weeks.
Fluorescence-activated cell sorter analysis (FACS)
FACS analysis was performed as described previously [36].
High cholesterol diet and harvest
After four weeks of reconstitution recipient mice consumed a
high-cholesterol diet (HCD) for 18 weeks (Ssniff based on
Research Diets D12108). Subsequently, mice were euthanized,
hearts and aortas were removed, and histologically prepared as
described previously [29,36].
Lipoprotein measurement and leukocyte count
Blood samples were collected by retro-orbital puncture before
and at the end of HCD after an overnight starvation. Serum total
cholesterol and triglyceride concentrations were assayed by
commercially available enzymatic assays according to the
manufacturer’s protocols (CHOL-H L and Triglyceride L-Type
from WAKO).
RNA extraction, cDNA synthesis, and quantitative real-
time PCR
Harvested organs were stored in RNAlater (Qiagen) at 280uC.
RNA was extracted from murine aortas and spleens using TRIzol
Reagent (invitrogen) utilizing a modified protocol. Homogeniza-
tion was performed using a rotor-stator dispergator (IKA). 1 mgo f
total RNA was transcribed into cDNA using the Transcriptor 1
st
Strand cDNA Synthesis Kit (Roche). The cDNA obtained was
subjected to quantitative real-time PCR with a Roche LightCycler
480 using the LightCycler 480 SYBR Green I Master (Roche).
mGapdh served as endogenous control. Amplification of potential
genomic DNA contamination was ruled out by using intron-
spanning primer pairs and subsequent reassurance through
melting curve analysis. The following primers were employed:
mGapdh: 59-TGC ACC ACC AAC TGC TTA G-39 (foward) and
59-GAT GCA GGG ATG ATG TTC-39 (reverse), mTraf-6: 59-
TGT TCT TAG CTG CTG GGG TGT-39 (foward) and 59-GAA
Figure 6. TRAF6 deficiency does not alter lipid deposition in
the abdominal aorta. Lethally irradiated 6 week old TRAF6
+/+/LDLR
2/2
mice received TRAF6-deficient (hatched bars, N=10)or competent fetal liver
c e l l s( w h i t eb a r s ,N=1 0 ) ,T R A F 6
+/2/LDLR
2/2 mice received TRAF6-deficient
fetal liver cells (black bars, N=10) only. Subsequently, all groups consumed
high cholesterol diet (HCD) for 18 weeks. Abdominal aortas were fixed in
formalin, pinned, and stainedwithoil red Oto detect lipid deposition. Oilred
O-positive staining in per cent of total area is shown as mean6SEM in the
upper panel (A), representative images are shown below (B).
doi:10.1371/journal.pone.0011589.g006
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the ratio of mTRAF6/mGAPDH was calculated. P values lower
than 0.05 were considered significant.
Oil red O staining for lipids of cryostat sections and
abdominal aortas
Frozen sections were air dried, fixed in 10% formalin for 10 min,
washed, submerged in 100% propyleneglycol (Fisher scientific),
incubated in oil red O (Sigma-Aldrich) for 25 min at 60uC, dipped
into 0.25% ammonia H2O (EM Science), and coverslipped with
glycerol gelatine (Sigma-Aldrich). Abdominal aortas were fixed with
10%formalin, opened longitudinally, pinned, stainedwithoilred O
solution (2.5 h, RT), and washed with 85% propylene glycol.
Immunohistochemistry
Cryostat sections (6 mm) of mouse aortic roots were air-dried,
fixed in acetone at 220uC, incubated with 0.3% H2O2, blocked
with 4% rabbit serum (Vector Laboratories), incubated with
primary antibodies (anti-mac-3, anti-a-actin, and anti-CD4 from
Pharmingen), incubated with corresponding secondary antibodies
(Vector Laboratories and Sigma-Aldrich), washed, incubated with
avidin-biotin complex (Vector Laboratories), developed with 3-
amino-9-ethylcarbazole (DAKO), counterstained with hematoxy-
lin (Sigma-Aldrich), and coverslipped with glycerol gelatine
(Sigma-Aldrich) as described previously [29]. Controls for
specificity used IgG controls (Pharmingen, Dako).
Picrosirius Red Staining for Type I Collagen
Air dried and formalin-fixed frozen sections were incubated for
3 h in 0.1% solution of picrosirius red (Polysciences) in saturated
aqueous picric acid (Sigma-Aldrich). Slides were rinsed twice in
0.01 N HCl and distilled water, dehydrated in 70%, 95%, 100%
ethanol, incubated in xylene, and mounted in Permount (Vector
Laboratories). Picrosirius red staining was analyzed by polarization
microscopy (Edmund Industrial Optics).
Macrophage preparation and stimulation with free fatty
acids and cholesterol
6 weeks after transplantation mice were euthanized and bones
were removed. Bone marrow was flushed out, cells were cleaned
Figure 7. TRAF6 deficiency does not modulate inflammatory reactivity of macrophages toward cholesterol and palmitic acid. Bone
marrow-derived macrophages were isolated from 6 week old TRAF6
+/+/LDLR
2/2 mice receiving TRAF6-deficient (hatched bars, N=4) or competent
fetal liver cells (white bars, N=4), were stimulated with 4 mg/ml cholesterol or 0.75 mM palmitic acid, and assayed for expression of IL-6 (A), MCP-1
(B), TNFa (C), and IL12-p70 (D) by cytometric bead array.
doi:10.1371/journal.pone.0011589.g007
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differentiated to macrophages with 50 ng/ml and subsequently
25 ng/ml M-CSF for 3 days each. Finally, macrophages were
stimulated after 24 h starvation with 0.75 mM palmitic acid (Sigma
Aldrich) respectively 4 mg/ml cholesterol diluted in ethanol and
BSA (Bovine Serum Albumin). The appropriate amount of
ethanol and BSA was added to the control. Supernatant was
collected and analyzed with cytometric bead array as previously
described [25].
Data analysis
Morphometric calculations of the tissue sections were analyzed
by a blinded observer using image pro plus 5.1 (MediaCyber-
netics). Data were presented as mean6SEM. Comparison of the
respective study groups used the Student’s two-tailed t-test. The p-
value refers to the control group and P,0.05 was considered
statistically significant.
Clinical study
325 patients undergoing coronary angiography were included in
the Tumor Necrosis Factor Receptor associated factors in
Cardiovascular Risk Study (TRAFICS) approved by the local
Institutional Review Board (ethic committees: Ethikkommission
der Albert- Ludwigs- Universita ¨t Freiburg, permit numbers EK
57/06 and EK 379/09). After written informed consent, blood
was drawn from all patients and total blood RNA was isolated by
Qiagen PAXgene blood RNA kit according to the manufacturer’s
instructions. Demographic and clinical characteristics were
documented. Patients were divided into three groups: no coronary
heart disease (No CHD), stable coronary heart disease (CHD), and
acute coronary syndrome (ACS). 1 mg RNA was transcribed into
cDNA with use of the transcriptor 1st strand cDNA synthesis kit
(Roche). The cDNA obtained was subjected to quantitative real
time-PCR with a Roche Light Cycler using the Light Cycler 480
SYBR Green I Master (Roche). As endogenous control, GAPDH
was employed. Conditions for quantification of TRAF6 mRNA
were 59-TTG TGC TAG TGC CCT CGA GAA-39 (forward) and
59-CTG GAG GAA AAA CTG GGG TGA-39 (reverse), 45 cycles
of 10 s at 95uC, 6 s at 60uC (57uC), and 7 s (10 s) at 72uC.
Conditions for quantification of GAPDH mRNA were: 59-GAA
GGT GAA GGT CGG AGT C-39 (forward) and 59-GAA GAT
GGT GAT GGG ATT TC-39 (reverse), 45 cycles of 10 s at 95uC,
6 s at 57uC, 10 s at 72uC. For normalization, the ratio of TRAF6/
GAPDH copy numbers was calculated. Only real-time PCRs with
an efficiency .1.9 and an error ,0.05 were analyzed. Statistical
analysis was performed with SPSS for Windows. Normal
distribution of variables was tested with the Shapiro Wilks test.
Differences across groups were compared by ANOVA followed by
the Bonferroni post hoc test for normal variables and the Kruskal
Wallis for non-normal variables. Results are presented as mean 6
standard deviation.
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Figure 8. TRAF6 expression in blood does not associate with
acute or chronic coronary heart disease. 325 patients undergoing
coronary angiography were divided into three groups: no coronary
heart disease (No CHD, N=77), stable coronary heart disease (CHD,
N=178), and acute coronary syndromes (ACS, N=70). TRAF6 and
GAPDH mRNA was analyzed by quantitative real-time PCR in total blood
RNA. Results are presented as mean6SD computed from the average
measurements obtained from each group.
doi:10.1371/journal.pone.0011589.g008
Table 2. Demographic and clinical characteristics of study
participants.
No CHD
(n=77) CHD (n=178)ACS (n=70)
Age (years) 62616 5 60,6* 6461
BMI (kg/m2) 28.260.5 27.560.3 27.860.5
% men 71 83 79
% diabetes 7,6 24.6 * 25.7 *
% hypertension 12,8 40.2 * 15.5 #
% smokers 9,1 27.4 * 14
SBP 131611 3 1 611 3 3 62
DBP 77617 7 617 9 61
Glucose 110641 1 4 631 2 0 66
Cholesterol 202671 8 2 621 * 19669
Triglycerides 150619 151691 7 1 618
LDL 116659 6 64* 9 9 67*
VLDL 35643 3 624 0 63 #
HDL 52634 8 615 3 65
Creatine kinase 109691 1 7 612 7096155 *,#
Pro-BNP 3896145 534698 13306509 *,#
*, p,0.05 vs controls.
#,p ,0.05 vs CHD.
doi:10.1371/journal.pone.0011589.t002
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